

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



IVD Medical Holding Limited

華檢醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1931)

CHANGE OF NON-EXECUTIVE DIRECTORS

The board (“**Board**”) of directors (“**Directors**”) of IVD Medical Holding Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) wishes to announce the appointment of Ms. Yao Haiyun (姚海雲) (“**Ms. Yao**”) as a non-executive Director with effect from 19 October 2021.

Mr. Chen Xingang (陳心剛) (“**Mr. Chen**”) has resigned as non-executive Director with effect from 19 October 2021, so as to devote more time to his personal commitments. He has also resigned as a director of Vastec Medical Equipment (Shanghai) Co., Ltd. and Vastec Medical Limited (both are subsidiaries of the Company).

The biographical details of Ms. Yao are set out below:

Ms. Yao Haiyun (姚海雲), aged 46, has been appointed as a non-executive Director. Ms. Yao has approximately 26 years of experience in finance and accounting work. She entered the finance department of Shinva Medical Instrument Co., Ltd. (“**Shinva**”, a controlling shareholder of the Company whose shares are currently listed on the Shanghai Stock Exchange) in 1995. Ms. Yao served various roles in the finance department of Shinva for the approximately 13 years thereafter, participating in the pre-listing process of Shinva, and its post-listing financial compliance process. Through such processes, Ms. Yao accumulated working experiences relating to finance and accounting of listed companies. Ms. Yao served in the finance department of various subsidiaries and related entities of Shinva in the approximately 13 years since 2008. She has been the person-in-charge of finance of Xinhua Surgical Instrument Co., Ltd. (新華手術器械有限公司) from July 2010, person-in-charge of finance of Shandong Shinva United Orthopedic Equipment Co., Ltd. (山東新華聯合骨科器材股份有限公司) from May 2015, and deputy head of finance department of Shandong Shinva Medical Instrument Co., Ltd (山東新華醫療器械股份有限公司) since July 2021. She acted as the person-in-charge of finance of Shinva GE Medical Systems Co., Ltd. (新華通用電氣醫療系統有限公司), and was also the person-in-charge of finance of Shandong Shinva Health Industry Co., Ltd. (山東新華健康產業有限公司), of Zibo Huanuo Health Industry Equity Investment Partnership (Limited Partnership) (淄博華諾健康產業股權投資合夥企業(有限合夥)), of Zibo Huakang Equity Investment Management Co., Ltd. (淄博華康股權投資管理有限公司) concurrently from May 2014 to April 2019. She was also responsible for the finance work related to the initial formation of Karlmed GmbH and Shandong Shinsun Biotechnology Co., Ltd (山東新華普陽生物技術有限公司) from May 2014 to April 2019. Ms. Yao has also been appointed as a director of Vastec Medical Equipment (Shanghai) Co., Ltd. and Vastec Medical Limited (both are subsidiaries of the Company).

Ms. Yao graduated from Hefei University of Technology in the People's Republic of China (the "PRC"), majoring in accounting and statistic, in July 1995. She has been conferred the Intermediate Level of Accounting Speciality by the Ministry of Finance of the PRC in May 2002.

The Company and Ms. Yao has entered into a letter of appointment, under which Ms. Yao will be appointed for an initial term from 19 October 2021 to the conclusion of the first general meeting of the Company after her appointment, subject to termination by either party giving not less than three months' written notice to the other. Her appointment is also subject to the provisions of the Articles of Association of the Company with regard to vacation of office of Directors, removal and retirement by rotation of Directors.

Ms. Yao is not expected to receive any remuneration from the Company for holding her office as a non-executive Director.

Save as disclosed above, Ms. Yao has confirmed that (i) she has no other relationship with any director, senior management, substantial or controlling shareholder of the Company, (ii) she does not currently hold any other position within the Group; (iii) she has not held any directorship in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (iv) she has no interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); and (v) there is no other information required to be disclosed pursuant to Rule 13.51(2) (h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The Company is not aware of any other matters in relation to Ms. Yao's appointment that need to be brought to the attention of shareholders of the Company.

Mr. Chen has confirmed that he has no disagreement with the Board, and there are no other matters relating to his resignation that need to be brought to the attention of shareholders of the Company.

The Board would like to express its sincere gratitude to Mr. Chen for his contribution and dedication to the Company during his tenure of office, and would like to extend a warm welcome to Ms. Yao.

By Order of the Board
IVD Medical Holding Limited
Ho Kuk Sing
Chairman and Executive Director

Hong Kong, 19 October 2021

As at the date of this announcement, the Board comprises three executive directors, namely, Mr. Ho Kuk Sing, Mr. Leung King Sun and Mr. Lin Xianya, three non-executive directors, namely, Mr. Yang Zhaoxu, Ms. Yao Haiyun and Mr. Chan Kwok King, Kingsley and three independent non-executive directors, namely, Mr. Lau Siu Ki, Mr. Zhong Renqian and Mr. Leung Ka Sing.

In this announcement, certain Chinese names of institutions, natural persons or other entities have been translated into English and included as unofficial translations for identification purposes only. In the event of any inconsistency, the Chinese names shall prevail.